## **Editorial Board**

P.A. Abrahamsson Department of Urology, Skåne University Hospital, Lund University, Malmö, Sweden

**B. B. Aggarwal** Cytokine Research Laboratory, Department of Experimental Therapeutics, University of Texas M.D. Anderson

Cancer Center, Houston, TX, USA

T. Akimoto Division of Partical Therapy and Department of Radiation Oncology, National Cancer Center East, Kashiwa,

Chiba, Japan

A. Argiris Division of Hematology/Oncology, UT Health Science Center at San Antonio, San Antonio, TX, USA

J. P. Armand Institut Claudius Regaud, Toulouse, France

V. I. Avramis Division of Hematology/Oncology, Childrens Hospital, Los Angeles, CA, USA

R. C. Bast
 Department of Translational Research, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA
 G. Bauer
 Abteilung Virologie, Institut für Medizinische Mikrobiologie und Hygiene, Universität Freiburg, Germany

E. E. Baulieu INSERM U488 and College de France, Le Kremlin-Bicetre, France

Y. Becker Department of Biochemistry, Faculty of Medicine, Hebrew University of Jerusalem, Ein Kerem, Jerusalem, Israel

E. J. Benz, Jr. Dana-Farber Cancer Institute, Boston, MA, USA

J. Bergh Department of Clinical and Molecular Medicine, Radiumhemmet, Karolinska Institute, Stockholm, Sweden

D. D. Bigner Department of Pathology, Duke University Medical Center, Durham, NC, USA

A. Böcking

Institute for Cytopathology, University of Düsseldorf, Germany

G. Bonadonna

Istituto Nazionale per lo Studio e la Cura dei Tumori, Milano, Italy

F. T. Bosman

Institute of Pathology, University of Lausanne, Switzerland

**G. Broich** Gruppo Policlinico di Monza, Monza, Italy

J. M. Brown Department of Radiation Oncology, Stanford Medical Center, Stanford, CA, USA

Ø. S. Bruland Department of Medical Oncology-Radiotherapy, Norwegian Radium Hospital, Oslo, Norway

M. M. Burger Novartis, Basel, Switzerland

M. Carbone Cancer Research Center of Hawaii, Honolulu, HI, USA

C. Carlberg Institute of Biomedicine, University of Eastern Finland, Kuopio, Finland
 J. Carlsson Department of Biomedical Radiation Sciences, Uppsala University, Sweden

A. F. Chambers Department of Oncology, London Regional Cancer Center, London, Ontario, Canada

P. Chandra Abt. für Molekularbiologie, Klinikum Wolfgang Goethe-Universität, Frankfurt am Main, Germany

L. Cheng Department of Pathology, Indiana University School of Medicine, Indianapolis, IN, USA

J.-G. Chung Department of Biological Science and Technology, China Medical University, Taichung, Taiwan, ROC

E. De Clercq Rega Institute for Medical Research, Katholieke Universiteit Leuven, Belgium
 W. De Loecker Department of Biochemistry, Katholieke Universiteit Leuven, Belgium
 W. Den Otter VUMC, Department of Urology, Amsterdam, The Netherlands

E. P. Diamandis Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, Ontario, Canada

G. Th. Diamandopoulos Department of Pathology, Harvard Medical School, Boston, MA, USA

D.W. Felsher Division of Oncology, Stanford University School of Medicine, Stanford, CA, USA

**J. A. Fernandez-Pol** Metalloproteomics, LLC, Chesterfield, MO, USA

I. J. Fidler Department of Cancer Biology, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA

A.P. Fields Department of Cancer Biology, College of Medicine, Mayo Clinic, Jacksonville, FL, USA

B. Fuchs Balgrist University Hospital, Zurich, Switzerland

**G. Gabbiani** Department of Pathology, University of Geneva, Switzerland

R. Ganapathi Levine Cancer Institute, Carolinas HealthCare System, Charlotte, NC, USA

A. F. Gazdar Hamon Center for Therapeutic Oncology Research, University of Texas Southeastern Medical Center, Dallas,

TX, USA

J.H. Geschwind Interventional Radiology Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA

A. Giordano Sbarro Institute for Cancer Research, Temple University, Philadelphia, PA, USA
 G. Gitsch Department of Gynecology and Obstetrics, University of Freiburg, Germany

**R. H. Goldfarb** Trudeau Institute, Saranac Lake, NY, USA

## ANTICANCER RESEARCH 34: (2014)

S. Hammarström Department of Immunology, University of Umeä, Sweden

I. Hellström Harborview Medical Center, Seattle, WA, USAL. Helson Sign Path Pharma, Inc., Quakertown, PA, USA

**R. M. Hoffman** Department of Surgery, University of California, San Diego, CA, USA

K.-S. Jeong
 Department of Pathology, College of Veterinary Medicine, Kyungpook National University, Daegu, South Korea
 S. C. Jhanwar
 Laboratory of Solid Tumor Genetics, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New

York, NY, USA

**J. V. Johannessen** Department of Pathology, The Norwegian Radium Hospital, Oslo, Norway

B. Kaina Institute of Toxicology, University of Mainz, Germany

P.-L. Kellokumpu-Lehtinen Department of Oncology and Radiotherapy, Tampere University Hospital, Tampere, Finland

B. K. Keppler School of Medicine, University of Vienna, Austria
 D. G. Kieback Klinikum Vest, Standort Marl, Marl, Germany
 R. Klapdor Medical Clinic, University of Hamburg, Germany

U. R. Kleeberg
 Praxis Altona, Hamburg, Germany
 P. Kleihues
 Department of Pathology, University Hospital Zürich, Switzerland
 E. Klein
 Department of Tumor Biology, Karolinska Institute, Stockholm, Sweden
 S. D. Kottaridis
 Department of Virology, Hellenic Anticancer Institute, Athens, Greece

G. R. F. Krueger Center of Anatomy II, University of Cologne Medical School, Cologne, Germany

D. W. Kufe Division of Medicine, Dana-Farber Cancer Institute, Boston, MA, USA

Pat M. KumarDepartment of Biological Sciences, Manchester Metropolitan University, Manchester, UKShant KumarDepartment Pathology, University of Manchester Medical School, Manchester, UKM. KurokiDepartment of Biochemistry, Fukuoka University School of Medicine, Fukuoka, Japan

O. D. Laerum Department of Pathology, The Gade Institute, University of Bergen, Norway

**F. J. Lejeune** Fondation du Centre Pluridisciplinaire d' Oncologie, CHUV, Lausanne, Switzerland

L. F. Liu Department of Pharmacology, UMD of New Jersey, Piscataway, NJ, USA

D. M. Lopez Department of Microbiology and Immunology, University of Miami School of Medicine, Miami, FL, USA

E. Lundgren Unit of Applied Cell and Molecular Biology, University of Umeä, Sweden

H. T. Lynch Department of Preventive Medicine and Public Health, Creighton University, Omaha, NE, USA

Y. Maehara Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan J. Maher Department of Research Oncology, Division of Cancer Studies, King's College London School of Medicine,

Guy's Hospital Campus, London, UK

**J. Marescaux** IRCAD, University of Strasbourg, France

J. Mark Department of Pathology, Kärnsjukhuset, Skövde, Sweden

S. Mitra The Methodist Hospital Research Institute (TMHRI), Houston, TX, USA
 M. Mueller Hochschule Furtwangen University, Villingen-Schwenningen, Germany
 F. M. Muggia New York University Cancer Institute, School of Medicine, NY, USA

M. J. Murphy, Jr. Hipple Cancer Research Center, Dayton, OH, USA

M. Namiki Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical

Science, Kanazawa City, Ishikawa, Japan

R. Narayanan Department of Biological Sciences, Florida Atlantic University, Boca Raton, FL, USA

K. Nilsson Rudbeck Laboratory, Department of Genetics and Pathology, Uppsala University Hospital, Sweden

S. Pathak Department of Cell Biology, University of Texas, Houston, TX, USA

J.L. Persson Section for Experimental Cancer Research, Clinical Research Center, Lund University, Malmö, Sweden

S. Pestka Department of Molecular Genetics and Microbiology, University of Medicine and Dentistry of New Jersey,

Piscataway, NJ, USA

G. J. Pilkington Department of Cellular and Molecules Neurooncology, School of Pharmacy and Biomedical Sciences,

University of Portsmouth, UK

C. D. Platsoucas
 College of Sciences, Old Dominion University, Norfolk, VA, USA
 F. Podo
 Laboratory of Cell Biology, Istituto Superione di Sanità, Rome, Italy

## ANTICANCER RESEARCH 34: (2014)

A. Polliack Department of Haematology, Hadassah University Hospital and Medical School, Jerusalem, Israel

**G. Rebel** IRCAD, Hopitaux Universitaires, Strasbourg, France

M. Rigaud Laboratory Biochimie et Génétique Molecules, Faculté de Médecine de Limoges, France

U. Ringborg
 Department of General Oncology, Karolinska Hospital, Stockholm, Sweden
 M. Roselli
 Department of Medical Oncology, University of Rome "Tor Vergata", Italy
 A. Schauer
 Zentrum Pathologie, Georg-August Universität, Göttingen, Germany

M. Schneider Department of Organic Chemistry, Bergische University, Wuppertal, Germany

A. Seth Laboratory of Molecular Pathology, Sunnybrook Research Institute and University of Toronto, Ontario, Canada

G. V. Sherbet Cancer Research Unit, University of Newcastle-upon-Tyne, UK

G.-I. Soma Department of Integrated and Holistic Immunology, Faculty of Medicine, Kagawa University,

Kagawa, Japan

G. S. Stein Department of Biochemistry, College of Medicine, University of Vermont, Burlington, VT, USA

T. Stigbrand Department of Immunology, Umeä University, Umeä, Sweden T. M. Theophanides Department of Chemistry, Technical University of Athens, Greece

B. Toth The Eppley Institute for Research in Cancer and Allied Diseases, Omaha, NE, USA
 P. M. Ueland Clinical Pharmacolocy Unit, Department of Pharmacology, University of Bergen, Norway
 H. Van Vlierberghe Department of Gastroenterology and Hepatology, Ghent University Hospital, Ghent, Belgium

R.G. Vile Department of Immunology, Mayo Clinic, Rochester, MN, USA

M. Weller Department of Neurology, University Hospital Zurich, Zurich, Switzerland

B. Westermark Rudbecklaboratoriet, Department of Genetics and Pathology, University of Uppsala, Sweden

Y. Yen Department of Molecular Pharmacology, City of Hope, Duarte, CA, USA

M.R.I. Young
 Ralph H. Johnson VA Medical Center, Medical University of South Carolina, Charleston, SC, USA
 B. Zumoff
 Division of Endocrinology and Metabolism, Beth Israel Medical Center, New York, NY, USA